Zhang L, Moffatt-Bruce SD, Gaughan AA, Wang JJ, Rajab A, Hadley GA (2009) An anti-CD103 immunotoxin promotes long-term survival of pancreatic islet allografts. Am J Transplant 9:2012-2023. doi: 10.1111/j.1600-6143.2009.02735.x PMID: 19645708
Objective: To determine whether blockade of the CD103 pathway represents a viable therapeutic strategy for intervention in organ allograft rejection and graft-vs-host disease.
Summary: These data document that depletion of CD103 expressing cells represents a viable strategy for therapeutic intervention in allograft rejection.
Usage: Recipient C57BL/6 mice received 2.0 mg/kg M290-SAP or Rat IgG-SAP on day 3 post-transplantation.
Related Products: Anti-CD103-SAP (Cat. #IT-50), Rat IgG-SAP (Cat. #IT-17)